Breast Cancer Research and Treatment

, Volume 123, Supplement 1, pp 49–52 | Cite as

Therapeutic approaches in young women with advanced or metastatic breast cancer

Brief Report


  1. 1.
    Cardoso F, Di LA, Lohrisch C, Bernard C, Ferreira F, Piccart MJ (2002) Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 13(2):197–207CrossRefPubMedGoogle Scholar
  2. 2.
    Orlando L, Colleoni M, Fedele P, Cusmai A, Rizzo P, D’Amico M et al (2007) Management of advanced breast cancer. Ann Oncol 18(Suppl 6):vi74–vi76CrossRefPubMedGoogle Scholar
  3. 3.
    MacFarlane R, Speers C, Masoudi H, Chia S (2008) Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series. ASCO Meeting Abstracts 26(suppl 15):1000Google Scholar
  4. 4.
    Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF et al (2009) Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20(12):1953–1958CrossRefPubMedGoogle Scholar
  5. 5.
    Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V et al (2008) Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 19(12):2012–2019CrossRefPubMedGoogle Scholar
  6. 6.
    Peppercorn J (2009) Breast cancer in women under 40. Oncology (Williston Park) 23(6):465–474Google Scholar
  7. 7.
    Adjuvant Breast Cancer Trials Collaborative Group (2007) Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst 99(7):516–525CrossRefGoogle Scholar
  8. 8.
    Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19(2):343–353PubMedGoogle Scholar
  9. 9.
    Agrawal A, Winterbottom L, Robertson JF, Cheung KL (2008) Goserelin plus anastrozole (G + A) as first-line systemic therapy for premenopausal estrogen receptor positive (ER+) advanced breast cancer (ABC)—clinical and endocrine data. ASCO Meeting Abstracts 26(15_suppl):1091Google Scholar
  10. 10.
    Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98(18):1285–1291CrossRefPubMedGoogle Scholar
  11. 11.
    Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R et al (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39(16):2318–2327CrossRefPubMedGoogle Scholar
  12. 12.
    Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98(2):229–238CrossRefPubMedGoogle Scholar
  13. 13.
    Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE et al (2005) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 104(2):236–239CrossRefPubMedGoogle Scholar
  14. 14.
    Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26(10):1664–1670CrossRefPubMedGoogle Scholar
  15. 15.
    Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V et al (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20(11):1771–1785CrossRefPubMedGoogle Scholar
  16. 16.
    O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812–2823CrossRefPubMedGoogle Scholar
  17. 17.
    Albain KS, Nag SM, Calderillo-Ruíz G, Jordaan JP, Llombart AC, Pluzanska A et al (2008) Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26(24):3950–3957CrossRefPubMedGoogle Scholar
  18. 18.
    Stockmans G, Deraedt K, Wildiers H, Moerman P, Paridaens R (2008) Triple-negative breast cancer. Curr Opin Oncol 20(6):614–620CrossRefPubMedGoogle Scholar
  19. 19.
    Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281CrossRefPubMedGoogle Scholar
  20. 20.
    Torrisi R, Colleoni M, Veronesi P, Rocca A, Peruzzotti G, Severi G et al (2007) Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer. Breast 16(1):73–80CrossRefPubMedGoogle Scholar
  21. 21.
    Fernández Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L et al (2010) Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev 36(1):33–42CrossRefPubMedGoogle Scholar
  22. 22.
    Valabrega G, Montemurro F, Aglietta M (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18(6):977–984CrossRefPubMedGoogle Scholar
  23. 23.
    Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792CrossRefPubMedGoogle Scholar
  24. 24.
    Reid A, Vidal L, Shaw H, de Bono J (2007) Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 43(3):481–489CrossRefPubMedGoogle Scholar
  25. 25.
    Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743CrossRefPubMedGoogle Scholar
  26. 26.
    Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391–400CrossRefPubMedGoogle Scholar
  27. 27.
    Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  1. 1.Department of Medical OncologyHospital de LeónLeónSpain

Personalised recommendations